Revenue

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Revenue

REVENUE

The following table summarizes the disaggregation of revenue by nature:

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2022		2021		2022		2021
Net product sales	$	11,485	$	11,405	$	22,793	$	22,203
Alliance revenues	199		159		387		301
Other revenues	203		139		355		272
Total Revenues	$	11,887	$	11,703	$	23,535	$	22,776

The following table summarizes GTN adjustments:

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2022		2021		2022		2021
Gross product sales	$	17,299	$	16,782	$	33,949	$	32,341
GTN adjustments(a)
Charge-backs and cash discounts	(1,750)		(1,720)		(3,513)		(3,306)
Medicaid and Medicare rebates	(2,624)		(2,139)		(4,708)		(3,857)
Other rebates, returns, discounts and adjustments	(1,440)		(1,518)		(2,935)		(2,975)
Total GTN adjustments	(5,814)		(5,377)		(11,156)		(10,138)
Net product sales	$	11,485	$	11,405	$	22,793	$	22,203

(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $123 million and $197 million for the three and six months ended June 30, 2022, and $85 million and $302 million for the three and six months ended June 30, 2021, respectively.

The following table summarizes the disaggregation of revenue by product and region:

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2022		2021		2022		2021
In-Line Products
Eliquis	$	3,235	$	2,792	6,446		5,678
Opdivo	2,063		1,910		3,986		3,630
Pomalyst/Imnovid	908		854		1,734		1,627
Orencia	876		814		1,668		1,572
Sprycel	544		541		1,027		1,011
Yervoy	525		510		1,040		966
Empliciti	77		86		152		171
Mature and other products	435		473		897		979
New Product Portfolio
Reblozyl	172		128		328		240
Abecma	89		24		156		24
Zeposia	66		28		102		46
Breyanzi	39		17		83		17
Inrebic	23		16		41		32
Onureg	32		12		55		27
Opdualag	58		—		64		—
Camzyos	3		—		3		—
Recent LOE Products(a)
Revlimid	2,501		3,202		$	5,298	$	6,146
Abraxane	241		296		455		610
Total Revenues	$	11,887	$	11,703	$	23,535	$	22,776
United States	$	8,268	$	7,388	$	15,962	$	14,398
International	3,427		4,124		7,154		8,023
Other(b)	192		191		419		355
Total Revenues	$	11,887	$	11,703	$	23,535	$	22,776

(a)    Recent LOE Products includes products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity.

(b)    Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.

Revenue recognized from performance obligations satisfied in prior periods was $184 million and $331 million for the three and six months ended June 30, 2022 and $146 million and $430 million for the three and six months ended June 30, 2021, respectively, consisting primarily of revised estimates for GTN adjustments related to prior period sales and royalties for out-licensing arrangements.